Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 61, Issue 3, Pages 769-775
Publisher
Wiley
Online
2014-10-17
DOI
10.1002/hep.27567
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV
- (2014) Fasiha Kanwal et al. HEPATOLOGY
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C
- (2013) Vasilios Papastergiou et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Is genotype 3 of the hepatitis C virus the new villain?
- (2013) Nicolas Goossens et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2013) JOURNAL OF HEPATOLOGY
- Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
- (2013) E. B. Tapper et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Pharmacotherapy for Hepatitis C
- (2012) D N Assis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
- (2010) S. Naggie et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
- (2009) Thierry Poynard et al. GASTROENTEROLOGY
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now